Eli Lilly-Innovent Biologics Score Expanded Use Approval of Tyvyt n Lung Cancer Patients In China

by Vandana Singh, Benzinga Editor
June 3, 2021 8:18 AM | 1 min read |
  • The National Medical Products Administration (NMPA) of China has approved Innovent Biologics Inc IVBXF and Eli Lilly And Co's LLY Tyvyt (sintilimab injection) in non-small cell lung cancer (NSCLC).
  • The approval is for expanded use of Tyvyt in combination with gemcitabine and platinum chemotherapy as first-line therapy for people with unresectable locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC).
  • It is the third NMPA-approved indication of Tyvyt, following the approval in December 2018 for relapsed or refractory classical Hodgkin's lymphoma, and the approval in February 2021 for the first-line treatment of non-squamous non-small cell lung cancer.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: LLY shares closed at $199.13 on Wednesday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: BiotechNewsHealth CareFDAGeneralBriefslung cancerNon-Small Cell Lung Cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!